{
    "clinical_study": {
        "@rank": "158021", 
        "arm_group": [
            {
                "arm_group_label": "Primary Breast Cancer"
            }, 
            {
                "arm_group_label": "Recurrent/Metastatic Breast Cancer"
            }
        ], 
        "brief_summary": {
            "textblock": "Primary objective:\n\n      The primary objective is to define the proteomic and molecular characteristics of primary\n      and recurrent/ metastatic breast tumours with special focus on the expression of S100\n      protein and the estrogen receptor (ER), progesterone receptor (PR) and epidermal growth\n      factor receptor 2 (HER2) genes\n\n      Secondary objective:\n\n        -  To expand our understanding of the complex molecular pathways dictating the progression\n           of breast cancer and their response to different treatment regimes.\n\n        -  To relate proteomic findings to survival data\n\n        -  To identify potential serum markers of breast cancer progression"
        }, 
        "brief_title": "Breast Cancer Proteomics and Molecular Heterogeneity", 
        "condition": [
            "Primary Breast Cancer", 
            "Recurrent/Metastatic Breast Cancer"
        ], 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "This is a translational study. Patient will undergo standard treatment and tissue and blood\n      samples will be taken at various time points:\n\n      Tissue: Fresh frozen (FF) and Formalin fixed paraffin embedded tissue (FFPE) will be\n      collected at time of surgery/biopsy of a primary or a recurrent/metastatic tumour tissue.\n\n      Blood: Two types of study bloods (non-heparinised and Ethylenediaminetetraacetic acid\n      (EDTA)) will be taken pre-neoadjuvant treatment (if applicable), pre- and post-operatively\n      of primary and recurrent/ metastatic breast cancer (if recurrent/metastatic diagnosis and no\n      biopsy/surgery required then study bloods will be taken prior to starting treatment).\n\n      Additional blood samples will be taken annually at follow-up visits for 5 years from primary\n      cases and for up to 2 years from recurrent/metastatic cases.\n\n      Non-heparinised blood will be processed to serum. Clinical data will be collected at all\n      times of biological sampling."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Patients diagnosed with primary breast cancer attending hospital for the resection of\n             their tumour tissue\n\n             Or\n\n             -Patients with suspected or confirmed recurrent or metastatic breast cancer (Patient\n             has a history of a biopsy- or surgically- (i.e. pathologically) confirmed primary\n             breast cancer) attending hospital for the resection/biopsy and/or treatment of tumour\n             tissue\n\n             Or\n\n             -Patient with suspected (but not necessarily biopsy confirmed) newly diagnosed stage\n             4 breast cancer attending hospital for the resection/biopsy and/or treatment of their\n             tumour tissue\n\n          2. Patients receiving neoadjuvant treatment are also eligible (if applicable)\n\n          3. Patients have to be \u2265 18 years of age\n\n          4. Patients must be able to give informed consent"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "All newly diagnosed breast cancer patients, recurrent and stage IV metastatic breast\n        cancer patients."
            }
        }, 
        "enrollment": {
            "#text": "1780", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01840293", 
            "org_study_id": "ICORG 09-07"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 23, 2014", 
        "location": {
            "contact": {
                "last_name": "Contact Person", 
                "phone": "01- 809 3000"
            }, 
            "facility": {
                "address": {
                    "city": "Dublin", 
                    "country": "Ireland"
                }, 
                "name": "Beaumont Hospital"
            }, 
            "investigator": [
                {
                    "last_name": "Arnold Hill, Prof", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Bryan Hennessy, Prof", 
                    "role": "Principal Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Ireland"
        }, 
        "number_of_groups": "2", 
        "official_title": "Breast Cancer Proteomics and Molecular Heterogeneity", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Ireland: Health Information and Quality Authority", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "February 2023", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Investigation of proteins and their pathways in primary breast cancer, which are associated with patient outcome.", 
            "measure": "Investigation of proteins and their pathways in primary breast cancer", 
            "safety_issue": "No", 
            "time_frame": "10 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01840293"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Comparison of the molecular profile between primary and recurrent/metastatic lesions in breast cancer", 
                "safety_issue": "No", 
                "time_frame": "10 years"
            }, 
            {
                "description": "Identification of novel molecular mechanisms of breast cancer recurrence, therapy resistance and/or metastasis", 
                "measure": "Identification of novel molecular mechanisms of breast cancer recurrence", 
                "safety_issue": "No", 
                "time_frame": "10 years"
            }, 
            {
                "description": "Determination of novel potential molecular targets that can be used to develop future prevention and treatment advances in patients with breast cancer", 
                "measure": "Determination of novel potential molecular targets", 
                "safety_issue": "No", 
                "time_frame": "10 years"
            }
        ], 
        "source": "ICORG- All Ireland Cooperative Oncology Research Group", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "ICORG- All Ireland Cooperative Oncology Research Group", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Observational Model: Cohort", 
        "study_type": "Observational", 
        "verification_date": "January 2014"
    }
}